Skip to main content

Table 1 Published series on dendritic cell-based immunotherapy in pancreatic cancer

From: Targeting dendritic cells in pancreatic ductal adenocarcinoma

Tumor-associated antigen Year Na Stage Pulsation R SD PD Median survival (months)
MUC1
 Pecher et al. [31] 2002 2 Unresectable cDNA   0 2  
 Kondo et al. [32] 2008 20 Unresectable Peptide 1 5 14 9.8b
 Lepisto et al. [33] 2008 12 Resectable Peptide 4    26
 Rong et al. [34] 2012 7 Unresectable Peptide   0 7  
 Shindo et al. [35] 2014 42 Unresectable mRNA 4 22 16 13.9
WT1
 Koido et al. [37] 2014 10 Unresectable Peptide   7 3  
 Takakura et al. [39], Tsukinaga et al. [40] 2015 7 Unresectable Peptide   6 1 10.8
 Mayanagi et al. [38] 2015 10 Unresectable Peptide   6 4 8.3
 Okamoto et al. [41] 2016 255 Unresectable Peptide     9.9
Mesothelin
 Thomas et al. [43] 2004 14 Unresectable Peptide Immunological response in 3 patients
KRAS
 Gjertsen et al. [45] 1996 5 Unresectable Peptide   3 2 5
hTERT, CEA, survivin
 Mehrotra et al. [55] 2017 12 Unresectable Peptide     7.7
CEA, HER2, WT1
 Kimura et al. [56] 2012 49 Unresectable Peptide 7 10 32 11.8
CEA, MUC1
 Nakamura et al. [59] 2009 12 Unresectable Peptide, lysate     9
Tumor cell lysate
 Bauer et al. [61] 2011 12 Unresectable Lysate 1 2 9 10.5
  1. PD progressive disease, R partial or complete response to therapy, SD stable disease
  2. aOnly patients with pancreatic cancer were considered.
  3. bMean survival time